{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:43:09Z","timestamp":1793191389774,"version":"4.5.0"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2022,3,21]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the harms of ezetimibe in people who need lipid-lowering treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Systematic review and meta-analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>Randomised controlled trials and cohort studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                  <jats:p>Studies comparing ezetimibe with placebo, standard care, or other lipid-lowering agents in people who need lipid-lowering treatment with a follow-up duration of at least six months (or 24 weeks). The relative effects for potential harms of ezetimibe were pooled by use of random effect pairwise meta-analyses for randomised controlled trials and the evidence from observational studies was narratively summarised. The certainty of evidence was assessed using the Grading of Recommendation Assessment, Development, and Evaluation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>48 randomised controlled trials with 28\u2009444 participants (median follow-up 34 weeks, range 24-312 weeks) and four observational studies with 1667 participants (median follow-up 282 weeks, range 72-400 weeks) were included. The meta-analyses of randomised trials showed moderate to high certainty that ezetimibe was not associated with cancer (relative risk 1.01; 95% confidence interval 0.92 to 1.11), fractures (0.90; 0.74 to 1.10), discontinuation due to any adverse event (0.87; 0.74 to 1.03), gastrointestinal adverse events leading to discontinuation (1.34; 0.58 to 3.08), myalgia or muscular pain leading to discontinuation (0.82; 0.51 to 1.33), neurocognitive events (1.48; 0.58 to 3.81), or new-onset diabetes (0.88; 0.61 to 1.28). The narrative analysis of observational studies provided consistent findings. No credible subgroup effects were identified for the harm outcomes, including shorter versus longer follow-up duration of trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ezetimibe results in little to no difference in adverse events or other undesirable effects compared with placebo, usual care or other lipid-lowering agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Review registration<\/jats:title>\n                  <jats:p>PROSPERO CRD42020187437.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjmed-2022-000134","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T11:45:06Z","timestamp":1655379906000},"page":"e000134","source":"Crossref","is-referenced-by-count":44,"title":["Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies"],"prefix":"10.1136","volume":"1","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chinese Evidence-based Medicine Centre, Cochrane China Centre, and MAGIC China Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southwest Hospital, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyue","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chinese Evidence-based Medicine Centre, Cochrane China Centre, and MAGIC China Centre, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chinese Evidence-based Medicine Centre, Cochrane China Centre, and MAGIC China Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safi U","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Aertgeerts","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, and Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiukui","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, and Department of Medicine, McMaster University, Hamilton, ON, Canada"},{"name":"Centre of Gerontology and Geriatrics\/National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China"},{"name":"School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertruida","family":"Bekkering","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chinese Evidence-based Medicine Centre, Cochrane China Centre, and MAGIC China Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Delvaux","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz","family":"Riaz","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Olav","family":"Vandvik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Department of Medicine, Innlandet Hospital Trust, Gj\u00f8vik, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoming","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chinese Evidence-based Medicine Centre, Cochrane China Centre, and MAGIC China Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0060-0287","authenticated-orcid":false,"given":"Sheyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Chinese Evidence-based Medicine Centre, Cochrane China Centre, and MAGIC China Centre, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"2025080500553328000_1.1.e000134.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.002"},{"key":"2025080500553328000_1.1.e000134.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"2025080500553328000_1.1.e000134.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008720"},{"key":"2025080500553328000_1.1.e000134.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1681"},{"key":"2025080500553328000_1.1.e000134.5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003042"},{"key":"2025080500553328000_1.1.e000134.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.011"},{"key":"2025080500553328000_1.1.e000134.7","unstructured":"Feingold KR , Anawalt B , Boyce A . Cholesterol Lowering Drugs. Endotext [Internet]: MDText. com, Inc, 2021."},{"key":"2025080500553328000_1.1.e000134.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02798-4"},{"key":"2025080500553328000_1.1.e000134.9","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000034044.95911.DC"},{"key":"2025080500553328000_1.1.e000134.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60739-3"},{"key":"2025080500553328000_1.1.e000134.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"2025080500553328000_1.1.e000134.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.039415"},{"key":"2025080500553328000_1.1.e000134.13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012502.pub2"},{"key":"2025080500553328000_1.1.e000134.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2025080500553328000_1.1.e000134.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002"},{"key":"2025080500553328000_1.1.e000134.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0801461"},{"key":"2025080500553328000_1.1.e000134.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.12.037"},{"key":"2025080500553328000_1.1.e000134.18","unstructured":"Feingold KR , Grunfeld C . Cholesterol lowering drugs. Endotext [Internet]: MDText. com, Inc, 2018."},{"key":"2025080500553328000_1.1.e000134.19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pharmthera.2016.11.001","article-title":"Intensive LDL-cholesterol lowering therapy and neurocognitive function","volume":"170","author":"Banach","year":"2017","journal-title":"Pharmacol Ther"},{"key":"2025080500553328000_1.1.e000134.20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40256-018-0301-4","article-title":"Statin use and gastrointestinal hemorrhage: a large retrospective cohort study","volume":"19","author":"Martinez","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025080500553328000_1.1.e000134.21","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0292-0"},{"key":"2025080500553328000_1.1.e000134.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804602"},{"key":"2025080500553328000_1.1.e000134.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069066","article-title":"PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: clinical practice guideline with risk stratified recommendations","volume":"377","author":"Hao","year":"2022","journal-title":"BMJ"},{"key":"2025080500553328000_1.1.e000134.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5191"},{"key":"2025080500553328000_1.1.e000134.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2025080500553328000_1.1.e000134.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"2025080500553328000_1.1.e000134.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2025080500553328000_1.1.e000134.28","unstructured":"Wells GA , Shea B , O\u2019Connell D . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford, 2000. Available: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2025080500553328000_1.1.e000134.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025080500553328000_1.1.e000134.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e1553"},{"key":"2025080500553328000_1.1.e000134.31","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jacl.2015.11.015","article-title":"Statin therapy with or without ezetimibe and the progression to diabetes","volume":"10","author":"Barkas","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2025080500553328000_1.1.e000134.32","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/pds.4237","article-title":"The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients","volume":"26","author":"Kim","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025080500553328000_1.1.e000134.33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.5114\/aoms.2017.71855","article-title":"Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study","volume":"14","author":"K\u0142osiewicz-Latoszek","year":"2018","journal-title":"Arch Med Sci"},{"key":"2025080500553328000_1.1.e000134.34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4158\/EP.13.1.11","article-title":"Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance","volume":"13","author":"Rivers","year":"2007","journal-title":"Endocr Pract"},{"key":"2025080500553328000_1.1.e000134.35","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40264-016-0444-7","article-title":"Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors","volume":"39","author":"Angamo","year":"2016","journal-title":"Drug Saf"},{"key":"2025080500553328000_1.1.e000134.36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093131"},{"key":"2025080500553328000_1.1.e000134.37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30060"},{"key":"2025080500553328000_1.1.e000134.38","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544050-00002"},{"key":"2025080500553328000_1.1.e000134.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124587","article-title":"Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Battaggia","year":"2015","journal-title":"PLoS One"},{"key":"2025080500553328000_1.1.e000134.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.08.103"},{"key":"2025080500553328000_1.1.e000134.41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00547","article-title":"Effects of Non-statin Lipid-Modifying agents on cardiovascular morbidity and mortality among statin-treated patients: a systematic review and network meta-analysis","volume":"10","author":"Chaiyasothi","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025080500553328000_1.1.e000134.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.08.038"},{"key":"2025080500553328000_1.1.e000134.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2008.02062.x"},{"key":"2025080500553328000_1.1.e000134.44","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014400","article-title":"Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: a frequentist network meta-analysis","volume":"98","author":"Zhao","year":"2019","journal-title":"Medicine"},{"key":"2025080500553328000_1.1.e000134.45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/joim.12614","article-title":"Can LDL cholesterol be too low? possible risks of extremely low levels","volume":"281","author":"Olsson","year":"2017","journal-title":"J Intern Med"},{"key":"2025080500553328000_1.1.e000134.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"key":"2025080500553328000_1.1.e000134.47","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.9"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2022-000134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T07:55:38Z","timestamp":1754380538000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2022-000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,5,4]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/bmjmed-2022-000134"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2022-000134","relation":{},"ISSN":["2754-0413"],"issn-type":[{"value":"2754-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}